Patient characteristics
| Characteristic . | Patients enrolled, no. (%)* . | Patients who completed program, no. (%)† . |
|---|---|---|
| Male | 52 (52) | 52 (54) |
| Mean age, y (range) | 54 (30-65) | 54 (30-65) |
| Durie & Salmon stage II | 29 (29) | 26 (27) |
| Durie & Salmon stage III | 67 (67) | 66 (69) |
| International Staging System 2 | 22/92 (24) | 22/88 (25) |
| International Staging System 3 | 14/92 (15) | 12/88 (14) |
| IgG myeloma | 57 (57) | 56 (58) |
| IgA myeloma | 18 (18) | 18 (19) |
| IgD myeloma | 1 (1) | 0 |
| Bence-Jones myeloma | 18 (18) | 17 (18) |
| Nonsecretory myeloma | 6 (6) | 5 (5) |
| β-2-microglobulin > 3.5 mg/dL | 33/95 (35) | 31/91 (34) |
| Albumin < 3.5 g/dL | 21/95 (22) | 21/92 (23) |
| Creatinine > 2 mg/dL | 11 (11) | 11 (11) |
| LDH above normal level | 17/91 (19) | 16/88 (18) |
| Presence of chromosome 13 deletion | 14/43 (33) | 13/39 (33) |
| HCT-specific comorbidity index ≥ 3 | 11 (11) | 10 (10) |
| Characteristic . | Patients enrolled, no. (%)* . | Patients who completed program, no. (%)† . |
|---|---|---|
| Male | 52 (52) | 52 (54) |
| Mean age, y (range) | 54 (30-65) | 54 (30-65) |
| Durie & Salmon stage II | 29 (29) | 26 (27) |
| Durie & Salmon stage III | 67 (67) | 66 (69) |
| International Staging System 2 | 22/92 (24) | 22/88 (25) |
| International Staging System 3 | 14/92 (15) | 12/88 (14) |
| IgG myeloma | 57 (57) | 56 (58) |
| IgA myeloma | 18 (18) | 18 (19) |
| IgD myeloma | 1 (1) | 0 |
| Bence-Jones myeloma | 18 (18) | 17 (18) |
| Nonsecretory myeloma | 6 (6) | 5 (5) |
| β-2-microglobulin > 3.5 mg/dL | 33/95 (35) | 31/91 (34) |
| Albumin < 3.5 g/dL | 21/95 (22) | 21/92 (23) |
| Creatinine > 2 mg/dL | 11 (11) | 11 (11) |
| LDH above normal level | 17/91 (19) | 16/88 (18) |
| Presence of chromosome 13 deletion | 14/43 (33) | 13/39 (33) |
| HCT-specific comorbidity index ≥ 3 | 11 (11) | 10 (10) |